Integrin β1 in Breast Cancer: Mechanisms of Progression and Therapy

Overview

Journal Breast Cancer

Specialty Oncology

Date 2024 Sep 29

PMID 39343856

Authors

Qionglian Huang

Jue Wang

Hanjuan Ning

Weiwei Liu

Xianghui Han

Affiliations

Soon will be listed here.

Abstract

The therapy for breast cancer (BC), to date, still needs improvement. Apart from traditional therapy methods, biological therapy being explored opens up a novel avenue for BC patients. Integrin β1 (ITGβ1), one of the largest subgroups in integrin family, is a key player in cancer evolution and therapy. Recent researches progress in the relationship of ITGβ1 level and BC, finding that ITGβ1 expression evidently concerns BC progression. In this chapter, we outline diverse ITGβ1-based mechanisms regarding to the promoted effect of ITGβ1 on BC cell structure rearrangement and malignant phenotype behaviors, the unfavorable patient prognosis conferred by ITGβ1, BC therapy tolerance induced by ITGβ1, and lastly novel inhibitors targeting ITGβ1 for BC therapy. As an effective biomarker, ITGβ1 undoubtedly emerges one of targeted-therapy opportunities of BC patients in future. It is a necessity focusing on scientific and large-scale clinical trials on the validation of targeted-ITGβ1 drugs for BC patients.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Moo T, Sanford R, Dang C, Morrow M . Overview of Breast Cancer Therapy. PET Clin. 2018; 13(3):339-354. PMC: 6092031. DOI: 10.1016/j.cpet.2018.02.006. View

Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y . ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. J Clin Invest. 2018; 128(5):1937-1955. PMC: 5919820. DOI: 10.1172/JCI95089. View

Hashemi M, Zaferani Arani H, Orouei S, Fallah S, Ghorbani A, Khaledabadi M . EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions. Biomed Pharmacother. 2022; 155:113774. DOI: 10.1016/j.biopha.2022.113774. View

Blandin A, Renner G, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M . β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer. Front Pharmacol. 2015; 6:279. PMC: 4656837. DOI: 10.3389/fphar.2015.00279. View

Sahana U, Wehland M, Simonsen U, Schulz H, Grimm D . A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure. Int J Mol Sci. 2023; 24(14). PMC: 10380763. DOI: 10.3390/ijms241411826. View

Takada Y, Ye X, Simon S . The integrins. Genome Biol. 2007; 8(5):215. PMC: 1929136. DOI: 10.1186/gb-2007-8-5-215. View

Yousefi H, Vatanmakanian M, Mahdiannasser M, Mashouri L, Alahari N, Monjezi M . Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. Oncogene. 2021; 40(6):1043-1063. DOI: 10.1038/s41388-020-01588-2. View

Mao L, Wang L, Xu J, Zou J . The role of integrin family in bone metabolism and tumor bone metastasis. Cell Death Discov. 2023; 9(1):119. PMC: 10086008. DOI: 10.1038/s41420-023-01417-x. View

10.

Campbell I, Humphries M . Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011; 3(3). PMC: 3039929. DOI: 10.1101/cshperspect.a004994. View

11.

Sinha B, Tokar E, Li J, Bushel P . Gene Expression Profiling Elucidates Cellular Responses to NCX4040 in Human Ovarian Tumor Cells: Implications in the Mechanisms of Action of NCX4040. Cancers (Basel). 2023; 15(1). PMC: 9818835. DOI: 10.3390/cancers15010285. View

12.

Guarin J, Fatherree J, Oudin M . Chemotherapy treatment induces pro-invasive changes in liver ECM composition. Matrix Biol. 2022; 112:20-38. PMC: 10690958. DOI: 10.1016/j.matbio.2022.08.002. View

13.

Sabherwal Y, Rothman V, Dimitrov S, LHeureux D, Marcinkiewicz C, Sharma M . Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp Cell Res. 2006; 312(13):2443-53. DOI: 10.1016/j.yexcr.2006.04.009. View

14.

Moritz M, Casali B, Stotzer U, Santos P, Selistre-de-Araujo H . Alternagin-C, an alpha2beta1 integrin ligand, attenuates collagen-based adhesion, stimulating the metastasis suppressor 1 expression in triple-negative breast tumor cells. Toxicon. 2022; 210:1-10. DOI: 10.1016/j.toxicon.2022.02.001. View

15.

Saadati F, Moritz J, Berner J, Freund E, Miebach L, Helfrich I . Patient-Derived Human Basal and Cutaneous Squamous Cell Carcinoma Tissues Display Apoptosis and Immunomodulation following Gas Plasma Exposure with a Certified Argon Jet. Int J Mol Sci. 2021; 22(21). PMC: 8584092. DOI: 10.3390/ijms222111446. View

16.

Zhou B, Li M, Xu X, Yang L, Ye M, Chen Y . Integrin αβ Targeting DGEA-Modified Liposomal Doxorubicin Enhances Antitumor Efficacy against Breast Cancer. Mol Pharm. 2021; 18(7):2634-2646. DOI: 10.1021/acs.molpharmaceut.1c00132. View

17.

Zuo X, Yang Y, Zhang Y, Zhang Z, Wang X, Shi Y . Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin α2β1-contacting-mediated activation of Wnt-β-catenin pathway. Cell Commun Signal. 2019; 17(1):142. PMC: 6836423. DOI: 10.1186/s12964-019-0464-x. View

18.

Moritz M, Eustaquio L, Micocci K, Nunes A, Santos P, de Castro Vieira T . Alternagin-C binding to αβ integrin controls matrix metalloprotease-9 and matrix metalloprotease-2 in breast tumor cells and endothelial cells. J Venom Anim Toxins Incl Trop Dis. 2018; 24:13. PMC: 5917863. DOI: 10.1186/s40409-018-0150-2. View

19.

Morozevich G, Kozlova N, Susova O, Karalkin P, Berman A . Implication of α2β1 integrin in anoikis of MCF-7 human breast carcinoma cells. Biochemistry (Mosc). 2015; 80(1):97-103. DOI: 10.1134/S0006297915010113. View

20.

Haidari M, Zhang W, Caivano A, Chen Z, Ganjehei L, Mortazavi A . Integrin α2β1 mediates tyrosine phosphorylation of vascular endothelial cadherin induced by invasive breast cancer cells. J Biol Chem. 2012; 287(39):32981-92. PMC: 3463327. DOI: 10.1074/jbc.M112.395905. View